RMD

Business profile & competitive position

ResMed Inc. (RMD) operates in the Healthcare sector, specifically the Medical - Instruments & Supplies industry. The company is a global developer of digital health and cloud-connected medical devices focused on sleep and breathing health. Its product portfolio includes CPAP, APAP, bilevel, and ventilation devices; masks; diagnostics; dental devices; and connected-care software. It also provides cloud-based Residential Care Software to home medical equipment suppliers, home health and hospice agencies, skilled nursing facilities, and senior living operators, selling products in more than 140 countries through subsidiaries and independent distributors.

The margin profile backs the idea of a durable competitive position. ResMed's net margin is 26.9% and its return on equity is 23.9%, both high for a capital-goods-oriented healthcare supplier. Those figures indicate the company converts revenue into profit efficiently and generates strong returns on shareholder equity, consistent with a business that benefits from recurring patient demand for replacement masks, accessories, and cloud monitoring services. A beta of 0.77 adds context: the stock has historically moved less than the broader market, a common trait for companies with stable, reimbursement-linked revenue streams. The combination of 26.9% net margin, 23.9% ROE, and low beta points to an established franchise rather than a speculative growth story.

Financial posture

ResMed currently carries a market capitalization of $32.3 billion and trades at a P/E ratio of 21.3. That valuation reflects both the company's growth profile and its standing as a high-quality, profitable medical-device franchise. A 26.9% net margin is well above what is typical for diversified healthcare suppliers, and the 23.9% ROE signals effective use of equity capital. The beta of 0.77 reinforces a defensive posture relative to the broad market.

No debt figure was included in the supplied financial snapshot, so any leverage conclusion would be speculative. What the numbers do show is a business generating substantial profitability from its installed base of devices, masks, and software subscriptions. The P/E of 21.3 can be read as the market pricing in moderate but steady growth rather than a premium hyper-growth multiple. The current stock price is $222.86, with an RSI of 49.4 and a 50-day EMA of $221.18, placing the price roughly in line with its near-term moving average.

Strategic priorities & outlook

ResMed's most recent 10-K outlines a strategy built on deepening its core sleep franchise while expanding into adjacent breathing and digital-health markets. Near-term priorities include:

• Growing and differentiating the sleep apnea portfolio by integrating AI and machine learning, simplifying care pathways, and expanding home diagnostics, including NightOwl and the VirtuOx IDTF acquisition.
• Accelerating market growth through awareness and education campaigns targeting patients, physicians, and special-interest groups for sleep apnea, COPD, and related comorbidities.
• Capitalizing on broader sleep and breathing health adjacencies such as COPD, neuromuscular disease, and restless legs syndrome, the latter supported by the Noctrix acquisition.
• Investing in an integrated, intelligent digital-health ecosystem delivered at home through AirView remote monitoring and the myAir patient engagement platform.

Operationally, ResMed reports two segments: Sleep and Breathing Health, and Residential Care Software. In fiscal 2026, devices generated approximately 51% of net revenue, masks, diagnostics, and accessories accounted for about 37%, and software represented roughly 12%. The company employed approximately 11,370 people and, as of the filing, had more than 35 million cloud-connected devices on AirView and over 12 million patients registered on myAir.

A notable near-term event is the June 2026 agreement to sell the MatrixCare business for $490 million in cash. The transaction, expected to close in the first quarter of fiscal 2027, is aimed at sharpening the company's focus on core sleep, breathing, and connected home-based healthcare. That concentration could make ResMed's revenue mix more directly tied to device and mask demand, as well as to its software growth.

Macro & geopolitical exposure

As a Medical - Instruments & Supplies company, ResMed faces exposures typical of the industry. Regulatory clearance and reimbursement policy are primary variables: device approvals, quality inspections, and payer coverage decisions can affect product launches and pricing. Because ResMed sells in more than 140 countries, currency fluctuations and local healthcare-funding regimes influence reported results. Trade policy matters as well; tariffs or supply-chain restrictions on electronics, semiconductors, and medical-grade plastics can raise production costs or limit component availability. Broader healthcare-spending trends and obesity-linked demand dynamics, including the rise of GLP-1 therapies, also sit within the macro backdrop because they shape the pool of diagnosed and treated sleep apnea patients.

Recent developments

ResMed has been active in both the news flow and the corporate calendar. On October 1, 2026, the company announced it will report first quarter fiscal 2027 earnings on October 29, 2026 after the close, according to Globe Newswire. The current consensus EPS estimate for that report is $2.68.

During September 2026, headlines from Defense World and MarketBeat highlighted ResMed's target of 12%-14% EPS growth, tied to expectations that GLP-1 patients are increasing demand for sleep therapy. On September 17, 2026, Defense World reported that Engineers Gate Manager LP held a $1.58 million stake in ResMed. The GLP-1 narrative is consistent with the 10-K's emphasis on awareness and education around sleep apnea and its comorbidities.

Earnings behavior & post-earnings drift

ResMed's earnings track record is strong on the headline beat metric. Over the last eight reported quarters, the company beat expectations seven times, an 88% beat rate, with an average earnings surprise of 3%. However, beating estimates has not reliably translated into a positive post-earnings drift. The average 5-day price move after earnings across those quarters is 0.24%, classified as flat.

The most recent four quarters illustrate the disconnect:

• August 6, 2026: actual EPS $2.95 versus an estimate of $2.89, a 2.1% positive surprise. The stock fell 5.06% the next day and rose 1.57% over the following five days.
• April 30, 2026: actual EPS $2.86 versus an estimate of $2.80, a 2.1% surprise. The stock fell 4.11% the next day and declined 3.24% over the next five days.
• January 29, 2026: actual EPS $2.81 versus an estimate of $2.74, a 2.6% surprise. The stock rose 0.27% the next day and gained 3.66% over the following five days.
• October 30, 2025: actual EPS $2.55 versus an estimate of $2.51, a 1.6% surprise. The stock fell 2.13% the next day and slid 1.03% over the next five days.

This pattern suggests that the market's real expectation may run ahead of the published consensus, causing even modest beats to be treated as priced-in events. The flat average 5-day drift supports the view that post-earnings directional edge in ResMed has been limited despite the consistent headline beats. The next report on October 29, 2026, with consensus EPS of $2.68, will offer the next test of whether execution can shift that dynamic.

If you want a deeper dive into how institutional analysts are weighing ResMed's valuation, earnings setup, and strategic pivot, explore the full institutional verdict on the platform.